B
Braidwell Portfolio holdings
AUM
$2.92B
1-Year Return
4.59%
This Quarter Return
+4.56%
1 Year Return
-4.59%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$2.72B
AUM Growth
-$442M
(-14%)
Cap. Flow
-$2.03B
Cap. Flow
% of AUM
-74.41%
Top 10 Holdings %
Top 10 Hldgs %
40.29%
Holding
93
New
5
Increased
13
Reduced
23
Closed
19
Top Buys
| 1 |
argenx
ARGX
|
$58.3M |
| 2 |
Penumbra
PEN
|
$32.1M |
| 3 |
Tourmaline Bio
TRML
|
$23.7M |
| 4 |
Inspire Medical Systems
INSP
|
$17.2M |
| 5 |
Krystal Biotech
KRYS
|
$14.7M |
Top Sells
| 1 |
Boston Scientific
BSX
|
$61.5M |
| 2 |
Natera
NTRA
|
$44.8M |
| 3 |
Merus
MRUS
|
$42.1M |
| 4 |
Glaukos
GKOS
|
$36M |
| 5 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
$34.9M |
Sector Composition
| 1 | Healthcare | 48.6% |
| 2 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
DCPH
26
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $18.9M | 0.69% |
1,169,490
-2,166,731
| -65% | -$34.9M |
|
27
Repligen
RGEN
$6.66B
| $18.5M | 0.68% |
102,698
-15,702
| -13% | -$2.82M |
|
28
Mineralys Therapeutics
MLYS
$2.04B
| $17.4M | 0.64% |
2,023,900
| – | – |
|
29
Harrow
HROW
$1.36B
| $16.8M | 0.62% |
1,498,584
-310,100
| -17% | -$3.47M |
|
30
Amgen
AMGN
$151B
| $16.8M | 0.62% |
58,200
+22,000
| +61% | +$6.34M |
|
31
Terns Pharmaceuticals
TERN
$602M
| $15M | 0.55% |
2,318,050
-522,002
| -18% | -$3.39M |
|
|
THRD
32
DELISTED
Third Harmonic Bio
THRD
| $14.4M | 0.53% |
1,316,018
-337,973
| -20% | -$3.71M |
|
33
Outset Medical
OM
$236M
| $13M | 0.48% |
160,028
| – | – |
|
34
Cullinan Oncology
CGEM
$409M
| $12.6M | 0.46% |
1,240,865
-668,000
| -35% | -$6.81M |
|
35
Structure Therapeutics
GPCR
$1.08B
| $11.4M | 0.42% |
+280,158
| New | +$11.4M |
|
36
Spyre Therapeutics
SYRE
$1.02B
| $11.1M | 0.41% |
+515,000
| New | +$11.1M |
|
|
37
Merus
MRUS
$4.94B
| $10.2M | 0.37% |
370,679
-1,530,658
| -81% | -$42.1M |
|
38
Dyne Therapeutics
DYN
$1.86B
| $10.1M | 0.37% |
755,811
-1,066,161
| -59% | -$14.2M |
|
39
Pulmonx
LUNG
$69.7M
| $10M | 0.37% |
787,954
-200,605
| -20% | -$2.56M |
|
40
Denali Therapeutics
DNLI
$2.16B
| $9.91M | 0.36% |
+461,769
| New | +$9.91M |
|
41
RAPT Therapeutics
RAPT
$198M
| $9.67M | 0.36% |
48,663
-86,651
| -64% | -$17.2M |
|
42
Transmedics
TMDX
$3.52B
| $9.29M | 0.34% |
117,701
-189,499
| -62% | -$15M |
|
|
DBVT
43
DBV Technologies
DBVT
$254M
| $7.47M | 0.27% |
784,329
-426,450
| -35% | -$4.06M |
|
44
Viridian Therapeutics
VRDN
$1.49B
| $7.04M | 0.26% |
323,102
-1,412,080
| -81% | -$30.8M |
|
45
Adaptive Biotechnologies
ADPT
$1.95B
| $6.65M | 0.24% |
1,357,490
+389,800
| +40% | +$1.91M |
|
46
HilleVax
HLVX
$105M
| $3.26M | 0.12% |
203,407
-1,245,839
| -86% | -$20M |
|
47
Compass Therapeutics
CMPX
$466M
| $496K | 0.02% |
317,761
-5,636,512
| -95% | -$8.79M |
|
|
AGEN
48
Agenus
AGEN
$132M
| – | – |
-315,352
| Closed | -$7.13M |
|
49
ALX Oncology
ALXO
$56.2M
| – | – |
-1,249,900
| Closed | -$6M |
|
50
AnaptysBio
ANAB
$596M
| – | – |
-1,049,823
| Closed | -$18.9M |
|